Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Reville PK, Wang B, Marvin-Peek J, Yuan B, et al. Blood 2025;145:3015-3029.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Reville PK, Wang B, Marvin-Peek J, Yuan B, et al. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood 2025;145:3015-3029.
PMID: 40179376